Regulation 91A Zero or nominal product reimbursement for ... vaccines and antiviralsF1F19
In the case of the drugs or medicines to which paragraph (2) applies, determining authorities must ensure that determinations under section 164 of the 2006 Act (remuneration of persons providing pharmaceutical services) in respect of pharmaceutical remuneration that relates to the supply or administration of those drugs or medicines either—
do not provide for or permit any reimbursement to be paid for the cost of the drug or medicine (and so the basic price of the drug or medicine, for Drug Tariff purposes, is zero); or
only provide for or permit nominal reimbursement to be paid for the cost of the drug or medicine.
This paragraph applies to—
a drug or medicine which is used for vaccinating or immunising people against respiratory syncytial virus, if the conditions set out in paragraph (3) are satisfied;
a drug or medicine which is used for vaccinating or immunising people against measles, mumps and rubella, if the conditions set out in paragraph (3) are satisfied; F5...
a drug or medicine which is used for vaccinating or immunising people against pertussis (whooping cough), if the conditions set out in paragraph (3) are satisfied; F7...
a drug or medicine which is used for vaccinating or immunising children against influenza, if the conditions set out in paragraph (3) are satisfied; F9...
a drug or medicine which is used for vaccinating or immunising people against human papillomavirus, if the conditions set out in paragraph (3) are satisfied; F11...
a drug or medicine which is used for vaccinating or immunising people against meningococcal disease caused by—
Neisseria meningitidis groups A, C, W and Y bacteria, or
Neisseria meningitidis group B bacteria,
if the conditions set out in paragraph (3) are satisfied;
a drug or medicine which is used for vaccinating or immunising people against tetanus, diphtheria and polio, if the conditions set out in paragraph (3) are satisfied; or
an antiviral drug or medicine which is used for preventing or treating coronavirus (“a coronavirus antiviral”), if the conditions set out in paragraph (4) are satisfied.
The conditions set out in this paragraph are—
the Secretary of State (references to whom in this regulation encompass both the Secretary of State for Health and Social Care and other Secretaries of State) has purchased F13the vaccines for supply as part of the health service;
the Secretary of State has made arrangements for all or part of the Secretary of State’s stock of the vaccines, purchased as mentioned in sub-paragraph (a), to be supplied to NHS pharmacists and LPS chemists, whether directly or via an intermediary, at no cost to the NHS pharmacists or LPS chemists;
NHS England has made arrangements for the administration of the vaccines from the stock mentioned in sub-paragraph (b) as part of F14a directed service; and
the F15... vaccine in question is from that stock and administered as part of that service.
The references in paragraph (3) to vaccines or the vaccine in question are references to the drugs or medicines in respect of which the conditions set out in paragraph (3) are to be satisfied by virtue of paragraph (2)(a) F17to (ag).
The conditions set out in this paragraph are—
the Secretary of State has purchased coronavirus antivirals of a particular type for supply as part of the health service;
the Secretary of State has made arrangements for all or part of the Secretary of State’s stock of that particular type of coronavirus antiviral, purchased as mentioned in sub-paragraph (a), to be supplied to NHS pharmacists and LPS chemists, whether directly or via an intermediary, at no cost to the NHS pharmacists or LPS chemists; and
the coronavirus antiviral in question—
is from that stock, or
is not from that stock but is nevertheless of the particular type of coronavirus antiviral that is available at no cost to NHS pharmacists and LPS chemists under the arrangements mentioned in sub-paragraph (b).
For the purposes of paragraph (4), the Secretary of State may characterise the particular type of coronavirus antivirals that are available at no cost to NHS pharmacists and LPS chemists solely by reference to the presentation of the drug or medicine (as well as by reference to its active ingredient, strength or any, or a combination of any, other distinguishing characteristics).
For the avoidance of doubt, determinations under section 164 of the 2006 Act that, in accordance with this regulation—
do not provide for or permit reimbursement to be paid for the cost of a drug or medicine (and so the basic price of the drug or medicine, for Drug Tariff purposes, is zero); or
only provide for or permit nominal reimbursement to be paid for the cost of a drug or medicine,
may nevertheless provide for or permit remuneration to be paid for any service provided by a NHS pharmacist or LPS chemist, in the course of which the drug or medicine is supplied or administered.
In this regulation, “nominal reimbursement” means, in the case of a drug or medicine that has been provided at no cost to a NHS pharmacist or LPS chemist, payment of an amount that is paid in place of the amount that the NHS pharmacist or LPS chemist would ordinarily make from the difference between—
the amount that they paid for the drug or medicine when they purchased it; and
the amount that they are paid by NHS England in respect of the cost of that drug or medicine (most commonly the basic price listed in the Drug Tariff), if they supply or administer that drug or medicine under arrangements for the provision of pharmaceutical or local pharmaceutical services.
For the purposes of paragraph (2)(ad), a drug or medicine is to be treated as a drug or medicine which is used for vaccinating or immunising children if (despite not being solely used for that purpose) it is mainly used for that purpose but it is also used for vaccinating or immunising people who have attained the age of 16 years.
Annotations
Textual amendments
- F1
Reg. 91A inserted (1.10.2022) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2022 (S.I. 2022/930), regs. 1(2), 5
- F2
Words in reg. 91A(2)(a) omitted (1.9.2024) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2024 (S.I. 2024/838), regs. 1(2), 2(3)(a)
- F3
Word in reg. 91A(2)(a) omitted (1.9.2024) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2024 (S.I. 2024/838), regs. 1(2), 2(3)(b)
- F4
Reg. 91A(2)(aa)(ab) inserted (1.9.2024) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2024 (S.I. 2024/838), regs. 1(2), 2(3)(c)
- F5
Word in reg. 91A(2)(ab) omitted (1.10.2024) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) (No. 2) Regulations 2024 (S.I. 2024/894), regs. 1(3), 2(2)(a)
- F6
Reg. 91A(2)(ac) inserted (1.10.2024) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) (No. 2) Regulations 2024 (S.I. 2024/894), regs. 1(3), 2(2)(b)
- F7
Word in reg. 91A(2)(ac) omitted (23.6.2025) by virtue of The National Health Service (Charges, Remission of Charges and Pharmaceutical Services etc.) (Amendment and Transitional Provisions) Regulations 2025 (S.I. 2025/636), regs. 1(2), 10(2)(a)
- F8
Reg. 91A(2)(ad) inserted (23.6.2025) by The National Health Service (Charges, Remission of Charges and Pharmaceutical Services etc.) (Amendment and Transitional Provisions) Regulations 2025 (S.I. 2025/636), regs. 1(2), 10(2)(b)
- F9
Word in reg. 91A(2)(ad) omitted (1.10.2025) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 63(2)(a)
- F10
Reg. 91A(2)(ae) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 63(2)(b)
- F11
Word in reg. 91A(2)(ae) omitted (20.7.2026) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2026 (S.I. 2026/702), regs. 1(2), 2(2)(a)
- F12
Reg. 91A(2)(af)(ag) inserted (20.7.2026) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2026 (S.I. 2026/702), regs. 1(2), 2(2)(b)
- F13
Word in reg. 91A(3)(a)-(c) substituted (1.9.2024) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2024 (S.I. 2024/838), regs. 1(2), 2(4)(a)
- F14
Words in reg. 91A(3)(c) substituted (23.6.2025) by The National Health Service (Charges, Remission of Charges and Pharmaceutical Services etc.) (Amendment and Transitional Provisions) Regulations 2025 (S.I. 2025/636), regs. 1(2), 10(3)
- F15
Word in reg. 91A(3)(d) omitted (1.9.2024) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2024 (S.I. 2024/838), regs. 1(2), 2(4)(b)
- F16
Reg. 91A(3A) inserted (1.9.2024) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2024 (S.I. 2024/838), regs. 1(2), 2(5)
- F17
Words in reg. 91A(3A) substituted (20.7.2026) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2026 (S.I. 2026/702), regs. 1(2), 2(3)
- F18
Reg. 91A(8) inserted (23.6.2025) by The National Health Service (Charges, Remission of Charges and Pharmaceutical Services etc.) (Amendment and Transitional Provisions) Regulations 2025 (S.I. 2025/636), regs. 1(2), 10(5)
- F19
Word in reg. 91A heading omitted (1.9.2024) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2024 (S.I. 2024/838), regs. 1(2), 2(2)